Latest Talius (ASX:TAL) News

Healthcare shares delivered mixed results as Percheron surged on a leadership change, while ResMed gained on stronger sales and portfolio changes.
Biotech funding, medical-device expansion and new software contracts shaped the week, but several small-cap gaps quickly lost ground.

Talius has secured a substantial $850,000 purchase order from New Zealand’s Hato Hone St John, adding 8,000 devices and boosting its recurring revenue by $55,000 annually.

Wellnex led the healthcare market after agreeing to sell Pain Away for up to A$21.3 million. Neuren and Lumos also rose strongly as sales, royalties and product orders improved.

Talius Group has secured a $1.65 million three-year deal to deploy its Talius One platform across three Queensland aged care facilities, boosting annual recurring revenue by $134,602 and deepening its relationship with Adventist Retirement Plus.

Talius Group maintained steady revenue in Q2 2026, boosted by $2 million in new aged care contracts and a 10% increase in active subscriptions.

Cann Group, OncoSil and Imugene led a busy healthcare week as investors chased FDA steps, cancer trial news and balance-sheet fixes. Elsewhere, revenue growth, hospital contracts and fresh funding kept money flowing into names with near-term commercial milestones.

Talius has landed a $1.15 million contract with Seventh-day Adventist Aged Care (North NSW), doubling its recent Queensland deal and adding over $100,000 in annual recurring revenue.

Speculative tech names drove the biggest swings this week, while data centres and software groups kept tapping investors for growth capital. The clearest pattern was simple: companies that showed revenue, contracts or cash support were rewarded, but some early price jumps faded fast when buyers stepped back.

Talius Group has reported its second consecutive quarter of positive operating cash flow, alongside an 11% annual increase in subscriptions and a $1.81 million revenue haul for Q1 FY26. The appointment of Pat Howard as CEO and a new $567k contract with Seventh-Day Adventist Aged Care signal momentum in the company’s push toward scalable growth.

Big gains came from contracts, approvals and takeover interest, while several capital raisings and debt deals drew a cooler response. Diagnostics, radiopharma and medtech led the week, with buyers rewarding companies that showed clear sales, supply or hospital access.

Talius Group has inked a Master Services Agreement with Adventist Retirement Plus to roll out its Nurse Call and Sleep Systems across two Queensland villages, setting the stage for wider expansion and recurring revenue growth.

Talius Group Limited reported a significant 31% decline in revenue for the year ended December 2025 but managed to reduce its net loss by 55%, reflecting cautious progress amid challenging conditions.